Brief Reports
Vol. 15 No. 1 (2021)
https://doi.org/10.4081/itjm.2020.1435

Potential pharmacological approach in the regulation of angiotensin-II conversion enzyme and dipeptidyl-peptidase 4 in diabetic COVID-19 patients

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 25 November 2020
Accepted: 3 December 2020
Published: 28 December 2020
1859
Views
641
Downloads
16
HTML
Diabetes, COVID-19, SARS-CoV-2, angiotensin- II conversion enzyme, dipeptidyl-peptidase 4.

Authors

Francesco Ferrara
francesco.ferrara@uslumbria1.it
https://orcid.org/0000-0001-9298-6783
Hospital Pharmacist Manager, Pharmaceutical Department, Usl Umbria 1, Perugia, Italy.
Antonio Vitiello
Clinical Pharmacologist, Pharmaceutical Department, Usl Umbria 1, Perugia, Italy.

The global pandemic caused by coronavirus disease 2019 (COVID-19) has caused more than 1 million deaths worldwide. Some vaccines in clinical trials have reached stage 3. In the meantime, the understanding of biological and pathophysiological mechanisms of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection is still unclear, such as the role that angiotensin-II conversion enzyme (ACE-2) and dipeptidyl-peptidase 4 (DPP-IV) may play in patients with diabetes related to COVID-19. The individual with diabetes is a known COVID-19 risk patient. Probably, the pharmacological regulation of the angiotensin renin system and ACE-2 on the one hand, and of the incretin system and DPP-IV on the other hand, could represent a therapeutic route of fundamental importance to reduce the risk of SARS-CoV-2 infection or of severe complications caused by infection.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
John Hopkins University. Available from: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
World Health Organization (WHO). DRAFT landscape of COVID-19 candidate vaccines. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020 doi: 10.1007/s00134-020-05991-x. [Epub ahead of print]. DOI: https://doi.org/10.1007/s00134-020-05991-x
Vitiello A, Ferrara F. Correlation between renin-angiotensin system and severe acute respiratory syndrome coronavirus 2 infection: what do we know. Eur J Pharmacol 2020;883:173373. DOI: https://doi.org/10.1016/j.ejphar.2020.173373
Jian S, Yushun W, Chuming L. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 2020;117:11727-34. DOI: https://doi.org/10.1073/pnas.2003138117
Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect 2020;9:601-4. DOI: https://doi.org/10.1080/22221751.2020.1739565
Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005;48:1168-72. DOI: https://doi.org/10.1007/s00125-005-1749-8
Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci 2020;262:118510. DOI: https://doi.org/10.1016/j.lfs.2020.118510
Vitiello A, Ferrara F. Therapeutic strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci 2020;105579. DOI: https://doi.org/10.1016/j.ejps.2020.105579
Lambeir AM, Durinx C, Scharpe S, DeMeester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.
Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53-73. DOI: https://doi.org/10.1078/0171-9335-00302
Lambeir AM. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94. DOI: https://doi.org/10.1080/713609354
Kaufman MB. ACE inhibitor-related angioedema: are your patients at risk?. P T. ? 2013;38:170-2.

How to Cite



Potential pharmacological approach in the regulation of angiotensin-II conversion enzyme and dipeptidyl-peptidase 4 in diabetic COVID-19 patients. (2020). Italian Journal of Medicine, 15(1). https://doi.org/10.4081/itjm.2020.1435